Identifying the genotype behind the phenotype: a role model found in VKORC1 and its association with warfarin dosing.

Genotype-phenotype studies in pharmacogenomics promise to identify the genetic factors that contribute substantially to variation in individual drug response. While most genetic association studies have failed to deliver this promise, several recent examples serve as a reminder that these associations do exist and can be identified when investigated using well-designed studies. Here, we describe the path taken to identify the association between common vitamin K epoxide reductase complex subunit 1 genetic variation and warfarin dosing in patients. We also describe the key elements that led the way, such as definition of the phenotype, confirmation of a genetic component, determination of biological plausibility and selection of genetic polymorphisms. We also describe several avenues that are yet to be explored for the specific vitamin K epoxide reductase complex subunit 1 warfarin example that can also be generalized as future directions for many genetic association studies in pharmacogenomics. These future avenues will be best explored using diverse approaches encompassing clinical, statistical and genomic methods currently being developed for genotype-phenotype studies in human populations.

[1]  M. Margaglione,et al.  A new vitamin K epoxide reductase complex subunit‐1 (VKORC1) mutation in a patient with decreased stability of CYP2C9 enzyme , 2007, Journal of thrombosis and haemostasis : JTH.

[2]  H. Halkin,et al.  Combined genetic profiles of components and regulators of the vitamin K-dependent γ-carboxylation system affect individual sensitivity to warfarin , 2006, Thrombosis and Haemostasis.

[3]  M. Ritchie,et al.  Different contributions of polymorphisms in VKORC1 and CYP2C9 to intra- and inter-population differences in maintenance dose of warfarin in Japanese, Caucasians and African-Americans , 2006, Pharmacogenetics and genomics.

[4]  Kevin L. Gunderson,et al.  Highly parallel genomic assays , 2006, Nature Reviews Genetics.

[5]  M. Charng,et al.  A novel functional VKORC1 promoter polymorphism is associated with inter-individual and inter-ethnic differences in warfarin sensitivity. , 2005, Human molecular genetics.

[6]  A. Need,et al.  Priorities and standards in pharmacogenetic research , 2005, Nature Genetics.

[7]  Francis S. Collins,et al.  Genes, environment and the value of prospective cohort studies , 2006, Nature Reviews Genetics.

[8]  M. Kohn,et al.  A gene-anchored map position of the rat warfarin-resistance locus, Rw, and its orthologs in mice and humans , 2000 .

[9]  T. Wienker,et al.  VKORC1 haplotypes and their impact on the inter-individual and inter-ethnical variability of oral anticoagulation , 2005, Thrombosis and Haemostasis.

[10]  E. Lange,et al.  Polymorphisms in the VKORC1 gene are strongly associated with warfarin dosage requirements in patients receiving anticoagulation , 2006, Journal of Medical Genetics.

[11]  L. Cardon,et al.  What makes a good case-control study? Design issues for complex traits such as endometriosis. , 2002, Human reproduction.

[12]  David B. Goldstein,et al.  Pharmacogenetics goes genomic , 2003, Nature Reviews Genetics.

[13]  S. Gabriel,et al.  Assessing the impact of population stratification on genetic association studies , 2004, Nature Genetics.

[14]  Mark I McCarthy,et al.  What makes a good genetic association study? , 2005, The Lancet.

[15]  M. Olivier.  A haplotype map of the human genome , 2003, Nature.

[16]  L. Cardon,et al.  Association study designs for complex diseases , 2001, Nature Reviews Genetics.

[17]  K. Lunetta,et al.  Testing for population subdivision and association in four case-control studies. , 2002, American journal of human genetics.

[18]  D. Goldstein,et al.  Will tomorrow's medicines work for everyone? , 2004, Nature Genetics.

[19]  J. Hirschhorn,et al.  A comprehensive review of genetic association studies , 2002, Genetics in Medicine.

[20]  C. Dina,et al.  Comment on "A Common Genetic Variant Is Associated with Adult and Childhood Obesity" , 2007, Science.

[21]  D. Greenblatt,et al.  Interaction of Warfarin With Drugs, Natural Substances, and Foods , 2005, Journal of clinical pharmacology.

[22]  Marylyn D. Ritchie,et al.  Parallel multifactor dimensionality reduction: a tool for the large-scale analysis of gene-gene interactions , 2006, Bioinform..

[23]  M. Shearer,et al.  Pharmacodynamic resistance to warfarin associated with a Val66Met substitution in vitamin K epoxide reductase complex subunit 1 , 2004, Thrombosis and Haemostasis.

[24]  R. Gibbs.  Deeper into the genome , 2005, Nature.

[25]  Hiroshi Sato,et al.  Functional SNPs in the lymphotoxin-α gene that are associated with susceptibility to myocardial infarction , 2002, Nature Genetics.

[26]  M. Rieder,et al.  Association of Vitamin K epoxide reductase complex 1 (VKORC1) variants with warfarin dose in a Hong Kong Chinese patient population , 2005, Pharmacogenetics and genomics.

[27]  M. Pirmohamed,et al.  Pharmacogenetics of warfarin: current status and future challenges , 2007, The Pharmacogenomics Journal.

[28]  Julie A. Johnson,et al.  Influence of coagulation factor, vitamin K epoxide reductase complex subunit 1, and cytochrome P450 2C9 gene polymorphisms on warfarin dose requirements , 2006, Clinical pharmacology and therapeutics.

[29]  H. Völzke,et al.  Comment on "A Common Genetic Variant Is Associated with Adult and Childhood Obesity" , 2007, Science.

[30]  B. Goh,et al.  Interethnic variability of warfarin maintenance requirement is explained by VKORC1 genotype in an Asian population , 2006, Clinical pharmacology and therapeutics.

[31]  J. Kahn.  Misreading race and genomics after BiDil , 2005, Nature Genetics.

[32]  J. Ott,et al.  Complement Factor H Polymorphism in Age-Related Macular Degeneration , 2005, Science.

[33]  Thomas A Trikalinos,et al.  Genetic associations in large versus small studies: an empirical assessment , 2003, The Lancet.

[34]  J. V. Moran,et al.  Initial sequencing and analysis of the human genome. , 2001, Nature.

[35]  Lyle J Palmer,et al.  Genetic Epidemiology 4 Shaking the tree : mapping complex disease genes with linkage disequilibrium , 2022 .

[36]  N. Risch,et al.  The importance of race and ethnic background in biomedical research and clinical practice. , 2003, The New England journal of medicine.

[37]  Marylyn D. Ritchie,et al.  GPNN: Power studies and applications of a neural network method for detecting gene-gene interactions in studies of human disease , 2006, BMC Bioinformatics.

[38]  Peter Wood,et al.  The impact of CYP2C9 and VKORC1 genetic polymorphism and patient characteristics upon warfarin dose requirements: proposal for a new dosing regimen. , 2005, Blood.

[39]  Koujirou Yamamoto,et al.  VKORC1 gene variations are the major contributors of variation in warfarin dose in Japanese patients , 2006, Clinical pharmacology and therapeutics.

[40]  E. Lander,et al.  Meta-analysis of genetic association studies supports a contribution of common variants to susceptibility to common disease , 2003, Nature Genetics.

[41]  L. Cardon,et al.  Population stratification and spurious allelic association , 2003, The Lancet.

[42]  Judy H. Cho,et al.  A Genome-Wide Association Study Identifies IL23R as an Inflammatory Bowel Disease Gene , 2006, Science.

[43]  M. Bloche.  Race-based therapeutics. , 2004, The New England journal of medicine.

[44]  Jason H. Moore,et al.  The Ubiquitous Nature of Epistasis in Determining Susceptibility to Common Human Diseases , 2003, Human Heredity.

[45]  P. Deloukas,et al.  Association of warfarin dose with genes involved in its action and metabolism , 2006, Human Genetics.

[46]  M. Margaglione,et al.  A polymorphism in the VKORC1 gene is associated with an interindividual variability in the dose-anticoagulant effect of warfarin. , 2005, Blood.

[47]  Andreas Fregin,et al.  Mutations in VKORC1 cause warfarin resistance and multiple coagulation factor deficiency type 2 , 2004, Nature.

[48]  H. Halkin,et al.  A coding VKORC1 Asp36Tyr polymorphism predisposes to warfarin resistance. , 2007, Blood.

[49]  Lon Cardon,et al.  Lymphotoxin-α Gene and Risk of Myocardial Infarction in 6,928 Cases and 2,712 Controls in the ISIS Case-Control Study , 2006, PLoS genetics.

[50]  A. Motulsky.  Drug reactions enzymes, and biochemical genetics. , 1957, Journal of the American Medical Association.

[51]  L. Schurgers,et al.  Congenital Deficiency of Vitamin K Dependent Coagulation Factors in Two Families Presents as a Genetic Defect of the Vitamin K-Epoxide-Reductase-Complex , 2000, Thrombosis and Haemostasis.

[52]  D. Allison,et al.  Detection of gene x gene interactions in genome-wide association studies of human population data. , 2007, Human heredity.

[53]  A. Khvorova,et al.  Identification of the gene for vitamin K epoxide reductase , 2004, Nature.

[54]  Dana C Crawford,et al.  The patterns of natural variation in human genes. , 2005, Annual review of genomics and human genetics.

[55]  M. Loriot,et al.  A vitamin K epoxide reductase complex subunit‐1 (VKORC1) mutation in a patient with vitamin K antagonist resistance , 2005, Journal of thrombosis and haemostasis : JTH.

[56]  J. Oldenburg,et al.  Homozygosity mapping of a second gene locus for hereditary combined deficiency of vitamin K-dependent clotting factors to the centromeric region of chromosome 16. , 2002, Blood.

[57]  H. McLeod,et al.  Pharmacogenomics: from bedside to clinical practice. , 2006, Human molecular genetics.

[58]  Timothy B. Stockwell,et al.  The Sequence of the Human Genome , 2001, Science.

[59]  F. Crick,et al.  Molecular Structure of Nucleic Acids: A Structure for Deoxyribose Nucleic Acid , 1953, Nature.

[60]  Deborah A Nickerson,et al.  Effect of VKORC1 haplotypes on transcriptional regulation and warfarin dose. , 2005, The New England journal of medicine.

[61]  M. Parker,et al.  Patient-Specific Factors Predictive of Warfarin Dosage Requirements , 2002, The Annals of pharmacotherapy.

[62]  Russ Altman,et al.  Pharmacogenomics: Challenges and Opportunities , 2006, Annals of Internal Medicine.

[63]  R. Cooper,et al.  Race and genomics. , 2003, The New England journal of medicine.

[64]  N. Stockbridge,et al.  BiDil for Heart Failure in Black Patients: The U.S. Food and Drug Administration Perspective , 2007, Annals of Internal Medicine.

[65]  D. Bentley,et al.  Whole-genome re-sequencing. , 2006, Current opinion in genetics & development.

[66]  H. Cordell.  Epistasis: what it means, what it doesn't mean, and statistical methods to detect it in humans. , 2002, Human molecular genetics.

[67]  V. Vitzthum.  A Number No Greater than the Sum of Its Parts: The Use and Abuse of Heritability , 2003, Human biology.

[68]  J. Greaves,et al.  Heritable Resistance to Warfarin in Rats , 1967, Nature.

[69]  D. Duggan,et al.  Recent developments in genomewide association scans: a workshop summary and review. , 2005, American journal of human genetics.

[70]  Lon R. Cardon,et al.  The complex interplay among factors that influence allelic association , 2004, Nature Reviews Genetics.

[71]  Clive Brown,et al.  Toward the $1000 human genome , 2005 .

[72]  J. Ioannidis,et al.  Replication validity of genetic association studies , 2001, Nature Genetics.

[73]  Howard L McLeod,et al.  Use of pharmacogenetics and clinical factors to predict the maintenance dose of warfarin , 2003, Thrombosis and Haemostasis.

[74]  L. Rohde,et al.  Role of dietary vitamin K intake in chronic oral anticoagulation: prospective evidence from observational and randomized protocols. , 2004, The American journal of medicine.

[75]  S. Hunt,et al.  Common VKORC1 and GGCX polymorphisms associated with warfarin dose , 2005, The Pharmacogenomics Journal.

[76]  F. Hu,et al.  A Common Genetic Variant Is Associated with Adult and Childhood Obesity , 2006, Science.

[77]  B. Horne,et al.  Genotypes of the cytochrome p450 isoform, CYP2C9, and the vitamin K epoxide reductase complex subunit 1 conjointly determine stable warfarin dose: a prospective study , 2006, Journal of Thrombosis and Thrombolysis.

[78]  S. O’Rahilly,et al.  Comment on "A Common Genetic Variant Is Associated with Adult and Childhood Obesity" , 2007, Science.

[79]  J. H. Moore,et al.  Multifactor-dimensionality reduction reveals high-order interactions among estrogen-metabolism genes in sporadic breast cancer. , 2001, American journal of human genetics.